Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

[A rare tympanic lesion - paracentesis led to an interesting diagnosis].

Laryngo- rhino- otologie·2018
Same author

[Improved quality of coronary diagnostics and interventions by virtual reality simulation].

Herz·2011
Same author

[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline].

Zeitschrift fur Gastroenterologie·2011
Same author

ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival.

Journal of neurology, neurosurgery, and psychiatry·2011
Same author

[How can the shift of refraction due to vitreous substitutes be avoided? Posterior chamber intraocular lens for patients suffering from diabetic retinopathy].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2011
Same author

Impact on health-related quality of life in kidney transplant recipients with late posttransplant anemia administered darbepoetin alfa: results from the STRATA study.

Transplantation proceedings·2011

相关实验视频

Updated: Jun 24, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

在乙型肝炎病毒亚型 adw 中,拉米丁耐药性风险增加了20倍.

B Zöllner, J Petersen, M Schröter

    Lancet (London, England)
    |April 6, 2001
    PubMed
    概括

    乙型肝炎病毒 (HBV) adw亚型携带者在抗病毒治疗期间面临的拉米武丁耐药性发展的风险高于ayw亚型携带者. 这种风险增加可能与乙型肝炎表面抗原 (HBsAg) 的同时变化有关.

    科学领域:

    • 肝病学和病毒学.
    • 抗病毒药物耐药性 抗病毒药物耐药性

    背景情况:

    • 慢性乙型肝炎病毒 (HBV) 感染需要长期的抗病毒治疗.
    • 拉米武丁是用于HBV治疗的常用核类比剂.
    • 了解影响 lamivudine 耐药性的因素对于有效的患者管理至关重要.

    研究的目的:

    • 研究HBV亚型 (adw和ayw) 对拉米丁耐药性发展的影响.
    • 在抗病毒治疗期间评估不同HBV亚型中拉米武丁耐药性的纵向风险.

    主要方法:

    • 对26名连续接受 lamivudine 治疗的慢性乙型肝炎患者进行长度研究.
    • 根据HBV亚型,患者被分为两组:13个adw携带者和13个ayw携带者.
    • 在整个治疗期间,监测拉米武丁耐药性的发展.

    主要成果:

    • 在13个adw载体中,有7个出现了拉米武丁耐药性.
    • 在13名艾滋病毒携带者中,只有1名患有拉米武丁耐药性.
    • 与Awy携带者相比,AdW携带者中拉米武丁耐药性的风险明显高于AWY携带者 (p=0.03).

    结论:

    更多相关视频

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
    09:17

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

    Published on: January 2, 2017

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    相关实验视频

    Last Updated: Jun 24, 2026

    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
    09:03

    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

    Published on: February 3, 2012

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
    09:17

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

    Published on: January 2, 2017

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

  • 乙型肝炎病毒的adw亚型与发展拉米丁耐药性的风险明显更高.
  • 在adw载体中这种增加的风险可能与在抗药性出现期间乙肝表面抗原 (HBsAg) 的同时变化有关.
  • 在接受 lamivudine 的慢性乙型肝炎患者中,可能需要特定亚型的监测和治疗策略.